New Evidence About the Dangers of Monsanto’s Roundup, the intercept, May 17 2016.
Roundup image via London Permaculture.
Until recently, the fight over Roundup has mostly focused on its active ingredient, glyphosate. But mounting evidence shows it’s not only glyphosate that’s dangerous, but also chemicals listed as “inert ingredients” in some formulations of Roundup and other glyphosate-based weed killers. Though they have been in herbicides — and our environment — for decades, these chemicals have evaded scientific scrutiny and regulation in large part because the companies that make and use them have concealed their identity as trade secrets.
Abstract
Co-Formulants in Glyphosate-Based Herbicides Disrupt Aromatase Activity in Human Cells below Toxic Levels, International Journal of Environmental Research and Public Health, 26 February 2016.
Pesticide formulations contain declared active ingredients and co-formulants presented as inert and confidential compounds.
We tested the endocrine disruption of co-formulants in six glyphosate-based herbicides (GBH), the most used pesticides worldwide. All co-formulants and formulations were comparably cytotoxic well below the agricultural dilution of 1% (18–2000 times for co-formulants, 8–141 times for formulations), and not the declared active ingredient glyphosate (G) alone.
The endocrine-disrupting effects of all these compounds were measured on aromatase activity, a key enzyme in the balance of sex hormones, below the toxicity threshold. Aromatase activity was decreased both by the co-formulants alone (polyethoxylated tallow amine—POEA and alkyl polyglucoside—APG) and by the formulations, from concentrations 800 times lower than the agricultural dilutions; while G exerted an effect only at 1/3 of the agricultural dilution.
It was demonstrated for the first time that endocrine disruption by GBH could not only be due to the declared active ingredient but also to co-formulants. These results could explain numerous in vivo results with GBHs not seen with G alone; moreover, they challenge the relevance of the acceptable daily intake (ADI) value for GBHs exposures, currently calculated from toxicity tests of the declared active ingredient alone.